 Bennett JonesIn The News Dominique Hussey in Bloomberg on Canada's Pharmaceutical IP RulesJuly 26, 2017 Authors Dominique T. HusseyChief Executive Officer Dominique Hussey comments in Bloomberg BNA on draft changes to Canada's patent litigation process for prescription drugs. She points out that the changes create new opportunities and challenges, introduce complexity into the litigation and will raise new procedural and substantive issues that have no precedent. The amendments could take effect as early as September 21, 2017, when the Comprehensive Economic Trade Agreement (CETA) that inspired the changes will be provisionally applied. Republishing Requests For permission to republish this or any other publication, contact Amrita Kochhar at kochhara@bennettjones.com. For informational purposes only This publication provides an overview of legal trends and updates for informational purposes only. For personalized legal advice, please contact the authors. AuthorsDominique T. Hussey, Chief Executive Officer • Co-Head of Innovation, Technology & Branding Practice Toronto • 416.777.6230 • husseyd@bennettjones.com |